Market Overview - The biopharmaceutical sector increased by 0.36% compared to the previous trading day, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Jindike (688670) saw a closing price of 30.90, with a significant increase of 20.00% and a trading volume of 192,400 shares, amounting to a transaction value of 572 million [1] - Rongchang Bio (688331) closed at 92.25, up 5.43%, with a trading volume of 68,800 shares and a transaction value of 635 million [1] - Sanofi (688336) closed at 68.39, up 4.59%, with a trading volume of 74,400 shares and a transaction value of 510 million [1] - Other notable performers include Olin Bio (616889) with a 4.43% increase and Hualan Bio (301207) with a 3.21% increase [1] Fund Flow Analysis - The biopharmaceutical sector experienced a net inflow of 20.94 million from institutional investors, while retail investors saw a net outflow of 57.02 million [2] - Jindike had a net inflow of 57.00 million from institutional investors, despite a net outflow of 19.76 million from retail investors [3] - Rongchang Bio also saw a net inflow of 32.94 million from institutional investors, with retail investors withdrawing 25.48 million [3]

Group 1 - The core point of the news is the performance and market position of Olin Bio, which saw a stock price increase of 5.46% to 24.52 CNY per share, with a total market capitalization of 9.953 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine (90.99%) [1] - The company has a diverse product portfolio, including A group and C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae conjugate vaccine (3.99%), and others [1] Group 2 - Huafu Fund has a significant holding in Olin Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 600,000 shares, representing 7.56% of the fund's net value [2] - The fund has achieved a year-to-date return of 33.75% and ranks 1847 out of 8134 in its category [2] - The fund manager, Liao Qingyang, has been in charge for 4 years and 18 days, with a total fund asset size of 216 million CNY [3]

欧林生物11月26日早间公告，公司于2025年11月25日向香港联交所递交了境外公开发行股份（H股）并 在香港联交所主板上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 ...

欧林生物(688319.SH)发布公告，公司于2025年11月25日向香港联合交易所有限公司(以下简称"香港联交 所")递交了境外公开发行股份(H股)并在香港联交所主板上市的申请，并于同日在香港联交所网站刊登 了本次发行上市的申请资料。 ...

成都欧林生物科技股份有限公司(以下简称"公司")于 2025 年 11 月 25 日向 香港联合交易所有限公司（以下简称"香港联交所"）递交了境外公开发行股份 （H 股）并在香港联交所主板上市（以下简称"本次发行上市"）的申请，并于同 日在香港联交所网站刊登了本次发行上市的申请资料。该申请资料为公司按照香 港证券及期货事务监察委员会及香港联交所的要求编制和刊发，为草拟版本，其 所载资料可能会适时作出更新及修订。 鉴于本次发行的认购对象仅限于符合相关条件的境外投资者及依据中国相关 法律法规有权进行境外证券投资的境内合格投资者，公司将不会在境内证券交易 所的网站和符合监管机构规定条件的媒体上刊登该申请资料，但为使境内投资者 及时了解该等申请资料披露的本次发行上市以及公司的其他相关信息，现提供该 申请资料在香港联交所网站的查询链接供查阅： 证券代码：688319 证券简称：欧林生物 公告编号：2025-065 成都欧林生物科技股份有限公司关于 向香港联合交易所有限公司递交 H 股发行上市的申请并刊发 申请资料的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性 ...

智通财经APP讯，欧林生物(688319.SH)发布公告，公司于2025年11月25日向香港联合交易所有限公司 (以下简称"香港联交所")递交了境外公开发行股份(H股)并在香港联交所主板上市的申请，并于同日在香 港联交所网站刊登了本次发行上市的申请资料。 ...

Core Viewpoint - 欧林生物 is a global, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines, particularly targeting unmet medical needs in "super bacteria vaccines" and "adult vaccines" [2][3]. Company Overview - 欧林生物 has successfully commercialized three products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine, establishing a strong commercial platform that generates stable cash flow [2]. - The company holds a leading market position in China for its Tetanus Toxoid Vaccine, with a market share exceeding 80% from 2022 to 2024 [2]. Product Pipeline - 欧林生物 has the most comprehensive pipeline targeting "super bacteria" vaccines globally, with candidates developed for five high-priority pathogens identified by the World Health Organization [2][3]. - The candidates include vaccines for Staphylococcus aureus, Helicobacter pylori, Pseudomonas aeruginosa, Acinetobacter baumannii, and Group A Streptococcus [2]. Financial Performance - Revenue for 欧林生物 is projected to be approximately RMB 5.47 billion in 2022, RMB 4.94 billion in 2023, and RMB 5.86 billion in 2024, with a six-month revenue of RMB 2.25 billion for 2024 and RMB 3.05 billion for 2025 [4]. - The company reported profits of RMB 26.58 million in 2022, RMB 11.44 million in 2023, and RMB 15.72 million in 2024, with a loss of RMB 30.72 million for the first half of 2024 [5][6]. Market Overview - The global vaccine market (excluding COVID-19 vaccines) is expected to grow from USD 52.9 billion in 2019 to USD 73.8 billion by 2024, with a CAGR of 6.9% [7]. - The Chinese vaccine market (excluding COVID-19 vaccines) is projected to increase from RMB 42.5 billion in 2019 to RMB 102 billion by 2024, with a CAGR of 19.1% [9]. Specific Market Insights - The Tetanus vaccine market in China is experiencing rapid growth, expected to rise from RMB 200 million in 2019 to RMB 800 million by 2024, with a CAGR of 40.2% [11]. - The Hib vaccine market in China is anticipated to grow from RMB 500 million in 2024 to RMB 2.4 billion by 2035, with a CAGR of 15.7% [13]. - The Meningococcal vaccine market in China is projected to grow from RMB 2.6 billion in 2019 to RMB 2.7 billion by 2024, with a stable CAGR of 1.4% [15].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. (Olin Bio) has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1]. Company Overview - Olin Bio is a global, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines. The company's strategic focus is on "super bacteria vaccines" and "adult vaccines," addressing significant unmet medical needs [4]. - Unlike many biotechnology companies that have yet to generate revenue, Olin Bio has a mature and robust commercialization platform, having successfully commercialized three products: adsorbed tetanus vaccine, Haemophilus influenzae type b (Hib) conjugate vaccine, and A/C group meningococcal polysaccharide conjugate vaccine [4][5]. - The company holds a leading market position in China for its adsorbed tetanus vaccine, with a market share exceeding 80% from 2022 to 2024 [4]. Product Pipeline - Olin Bio possesses the most comprehensive pipeline targeting "super bacteria" vaccines globally. The company is strategically developing innovative candidate vaccines against five pathogens, including: - Recombinant Staphylococcus aureus vaccine targeting Staphylococcus aureus, listed as a "high priority" by the WHO [5]. - Oral recombinant Helicobacter pylori vaccine [5]. - Recombinant Pseudomonas aeruginosa vaccine [5]. - Recombinant Acinetobacter baumannii protein vaccine [5]. - Group A Streptococcus vaccine [5]. - The company is also exploring the development of combination vaccines targeting multiple super bacteria to provide broad protection against antibiotic-resistant infections [5]. Financial Performance - Revenue for Olin Bio was approximately RMB 547 million in 2022, projected to be RMB 494 million in 2023, and expected to rise to RMB 586 million in 2024. For the first half of 2024 and 2025, revenues are estimated at RMB 225 million and RMB 305 million, respectively [6]. - The company reported profits of RMB 26.58 million in 2022, with a decline to RMB 11.44 million in 2023, and a projected profit of RMB 15.72 million in 2024. A loss of RMB 30.72 million is anticipated for the first half of 2024, with a recovery to RMB 13.23 million in the first half of 2025 [7][8]. Industry Overview - The global vaccine market (excluding COVID-19 vaccines) is projected to grow from USD 52.9 billion in 2019 to USD 73.8 billion by 2024, with a compound annual growth rate (CAGR) of 6.9%. By 2035, the market is expected to reach USD 149.5 billion, with a CAGR of 6.6% from 2024 to 2035 [9]. - In China, the vaccine market (excluding COVID-19 vaccines) is expected to grow from RMB 42.5 billion in 2019 to RMB 102 billion by 2024, with a CAGR of 19.1%. By 2035, the market is projected to reach RMB 382.5 billion, with a CAGR of 12.8% from 2024 to 2035 [11]. - The tetanus vaccine market in China has seen rapid growth, increasing from RMB 200 million in 2019 to RMB 800 million by 2024, with a CAGR of 40.2% [13].

Company Overview - 欧林生物 is a global, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines, particularly in the areas of "superbug vaccines" and "adult vaccines" [2][3] - Unlike many biotechnology companies that have yet to generate revenue, 欧林生物 has a mature commercialization platform with three products already commercialized: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [2] Market Position - The company's Tetanus Toxoid Vaccine holds a leading market position in China, with a market share exceeding 80% from 2022 to 2024 [2] - 欧林生物 possesses the most comprehensive pipeline targeting "superbugs" globally, addressing significant public health challenges due to antibiotic resistance [2][3] Product Pipeline - The company is developing a 1.1 class innovative superbug candidate vaccine targeting five pathogens, including: - Recombinant Staphylococcus aureus Vaccine (rFSAV) - Oral Recombinant Helicobacter pylori Vaccine (rHPV) - Recombinant Pseudomonas aeruginosa Vaccine (rFPAV) - Recombinant Acinetobacter baumannii Protein Vaccine (rABV) - Group A Streptococcus Vaccine (GAS Vaccine) [2] Financial Performance - Revenue for 欧林生物 is projected as follows: - 2022: approximately 547 million RMB - 2023: approximately 494 million RMB - 2024: approximately 586 million RMB - 2024 (first half): approximately 225 million RMB - 2025 (first half): approximately 305 million RMB [4][6] - Profit figures are as follows: - 2022: approximately 26.58 million RMB - 2023: approximately 11.44 million RMB - 2024: approximately 15.72 million RMB - 2024 (first half): approximately -30.72 million RMB - 2025 (first half): approximately 13.23 million RMB [5][6] Industry Overview - The global vaccine market (excluding COVID-19 vaccines) is expected to grow from 52.9 billion USD in 2019 to 73.8 billion USD by 2024, with a CAGR of 6.9% [8] - The Chinese vaccine market (excluding COVID-19 vaccines) is projected to grow from 42.5 billion RMB in 2019 to 102 billion RMB by 2024, with a CAGR of 19.1% [8] - The Tetanus vaccine market in China is experiencing rapid growth, expected to increase from 200 million RMB in 2019 to 800 million RMB by 2024, with a CAGR of 40.2% [10]

Group 1 - The core viewpoint of the article is that Chengdu Olymvax Biopharmaceuticals Inc. has submitted an application to list on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Olymvax is described as a globally-oriented, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines [1] - Unlike many biotechnology companies that have yet to generate revenue, Olymvax has a mature and robust commercialization platform, having successfully commercialized three products: adsorbed tetanus vaccine, Haemophilus influenzae type b conjugate vaccine, and group A and C meningococcal polysaccharide conjugate vaccine [1]